Regulatory dispatch
KPV: how it got to PCAC
Background
KPV (Lys-Pro-Val) is a tripeptide corresponding to the C-terminal three residues of alpha-melanocyte-stimulating hormone (alpha-MSH). It has no FDA-approved indication, no marketing authorization in any major jurisdiction, and no USP or NF monograph. As with other unapproved peptides, its lawful presence in the U.S. drug supply depends entirely on whether it can be compounded under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
KPV is now scheduled for review at the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23-24, 2026, where the committee will consider it alongside BPC-157, TB-500, and MOTs-C-related bulk drug substances (FDA — July 23-24, 2026 PCAC meeting).
The original nomination
KPV was nominated to the 503A bulk drug substances list during the original public nomination window FDA opened in 2013–2014 after the Drug Quality and Security Act was enacted. The agency received a large volume of nominations during that period, with KPV among the peptide-class submissions (FDA — Bulk Drug Substances Used in Compounding).
Category 2 placement
Following FDA’s preliminary evaluation, KPV was placed in “Category 2” — the bucket for substances FDA had identified as raising significant safety concerns and which the agency did not intend to cover under enforcement discretion while the formal 503A list was under development (FDA — Significant Safety Risks).
The factors FDA generally weighs for Category 2 placement include the absence of an FDA-approved drug product containing the substance, the absence of a USP or NF monograph, limited large-scale human safety data, and questions about manufacturing quality and impurity profiles for bulk material entering the compounding supply chain.
The published evidence base
KPV’s published evidence base is older and somewhat better characterized mechanistically than that of the other peptides on the July 2026 agenda, although it remains predominantly preclinical.
A 2003 study by Getting and colleagues in the Journal of Pharmacology and Experimental Therapeutics reported that KPV reduced leukocyte accumulation in a mouse peritonitis model and concluded that the tripeptide’s anti-inflammatory action did not appear to require melanocortin-receptor binding (PMID 12750433).
KPV exhibits an anti-inflammatory effect that is clearly different from that of the core MSH peptides. KPV is unlikely to mediate its effects through melanocortin receptors but is more likely to act through inhibition of IL-1beta functions.
A 2008 Gastroenterology paper by Dalmasso and colleagues at Emory University reported that KPV is transported into intestinal epithelial cells via the PepT1 di/tri-peptide transporter and that oral KPV reduced inflammation in DSS- and TNBS-induced mouse models of colitis (PMID 18061177). The authors described inhibition of NF-kB and MAPK signaling as the proposed intracellular mechanism.
Subsequent preclinical work has examined KPV in additional inflammatory and infectious contexts, but no large randomized clinical trials in humans appear in the published literature as of this writing.
Removal from Category 2 and route to PCAC
In April 2026, FDA announced that KPV had been removed from Category 2 because the original nominations were withdrawn by the nominators. Removal from Category 2 does not place a substance on the 503A Bulks List — it only ends the prior categorization. The agency simultaneously announced that it would take KPV, along with BPC-157, TB-500, and MOTs-C, to the PCAC for a full review at the July 23-24, 2026 meeting (FDA — July 23-24, 2026 PCAC meeting).
What the July 2026 meeting will weigh
The committee’s review will follow FDA’s standard four-factor framework: physical and chemical characteristics, safety, evidence of effectiveness, and historical use in compounded drug products.
KPV is a small, well-characterized tripeptide with straightforward synthesis and analytical methods, which simplifies the chemistry portion of the review. The safety record in published preclinical work is broadly unremarkable, and no notable signals from the limited human use have appeared in the indexed literature, but the committee may weigh the absence of large controlled human trials against the relatively long history of laboratory study. The effectiveness question turns on how the committee interprets a body of evidence that is mechanistically coherent but predominantly preclinical and concentrated in colitis and skin-inflammation models. Historical compounding use in the United States is documented but, as with BPC-157, concentrated in the post-2013 period.
What’s at stake
A favorable PCAC vote followed by FDA rulemaking would create the first lawful 503A compounding pathway for KPV in the United States. An unfavorable vote, or no FDA action, leaves KPV outside the regulated compounding pathway — neither monograph-covered nor a component of an FDA-approved drug, and therefore not eligible for 503A compounding by operation of the statute. A separate “clinical need” analysis would be required before any path to inclusion on the 503B list for outsourcing facilities.